cilostazol has been researched along with Cerebral Hemorrhage in 23 studies
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 9.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 8.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Although long-term treatment with the oral anticoagulant warfarin is widely used to prevent cardioembolic ischemic stroke, it has been reported that warfarin can exacerbate hemorrhagic transformation (HT) after cerebral ischemia." | 7.79 | Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice. ( Egashira, Y; Hara, H; Ito, H; Kitashoji, A; Mishiro, K; Shimazawa, M; Suzuki, Y; Tsuruma, K, 2013) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Cilostazol pre-treatment reduced the intracranial hemorrhage volume with sufficient inhibition of platelet aggregation, and motor function was improved by cilostazol treatment." | 5.46 | Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier. ( Hara, H; Imai, T; Ishisaka, M; Ito, H; Iwama, T; Kozawa, O; Matsukawa, H; Mishiro, K; Nagashima, K; Shimazawa, M; Takagi, T; Tsujimoto, M; Tsuruma, K; Yoshimura, S, 2017) |
| "Although dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the recurrence of ischemic stroke while significantly increasing the bleeding events compared with monotherapy, the CSPS." | 5.41 | Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Ishida, N; Isobe, M; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Okada, Y; Omae, K; Origasa, H; Sakai, N; Tanaka, K; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2021) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| " The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage-Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of cilostazol, probucol, or both on IMT in patients with stroke." | 5.24 | Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study. ( Kim, YJ; Kwon, SU; Lee, J; Seo, WK, 2017) |
| " This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function." | 5.22 | Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage. ( Hong, KS; Kwon, SU; Lee, J; Lee, JS; Oh, MS; Yu, KH, 2016) |
| "PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage was designed to compare cilostazol and aspirin and to assess the effect of adding probucol, a lipid-lowering and anti-oxidative agent, in patients at high risk of haemorrhagic stroke." | 5.20 | Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. ( Hong, KS; Kim, BJ; Kwon, SU; Lee, JY, 2015) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 5.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "While previous meta-analysis have investigated the efficacy of cilostazol in the secondary prevention of ischemic stroke, they were criticized for their methodology, which confused the acute and chronic phases of stroke." | 4.90 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis. ( Chen, S; Malaguit, J; Pu, J; Shi, L; Xu, L; Zhang, J, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Although long-term treatment with the oral anticoagulant warfarin is widely used to prevent cardioembolic ischemic stroke, it has been reported that warfarin can exacerbate hemorrhagic transformation (HT) after cerebral ischemia." | 3.79 | Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice. ( Egashira, Y; Hara, H; Ito, H; Kitashoji, A; Mishiro, K; Shimazawa, M; Suzuki, Y; Tsuruma, K, 2013) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Prior intracerebral hemorrhage (ICH) is associated with increased risk of ischemic stroke." | 3.01 | Prior intracerebral hemorrhage and white matter hyperintensity burden on recurrent stroke risk. ( Heo, SH; Kwon, HS; Kwon, SU; Park, JH, 2021) |
| "Cilostazol pre-treatment reduced the intracranial hemorrhage volume with sufficient inhibition of platelet aggregation, and motor function was improved by cilostazol treatment." | 1.46 | Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier. ( Hara, H; Imai, T; Ishisaka, M; Ito, H; Iwama, T; Kozawa, O; Matsukawa, H; Mishiro, K; Nagashima, K; Shimazawa, M; Takagi, T; Tsujimoto, M; Tsuruma, K; Yoshimura, S, 2017) |
| "Cilostazol is an antiplatelet drug often used in Asia; however, it is rarely used in the western hemisphere, particularly for stroke patients." | 1.37 | Cilostazol: a drug particularly effective for Asians? ( Kim, JS; Shinohara, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JH | 3 |
| Kwon, SU | 6 |
| Kwon, HS | 1 |
| Heo, SH | 3 |
| Tsai, HH | 1 |
| Hsieh, YC | 1 |
| Lin, JS | 1 |
| Kuo, ZT | 1 |
| Ho, CY | 1 |
| Chen, CH | 1 |
| Chang, CF | 1 |
| Kim, BJ | 3 |
| Kim, YJ | 3 |
| Hong, KS | 4 |
| Wong, LKS | 2 |
| Yu, S | 2 |
| Hwang, YH | 2 |
| Lee, JS | 3 |
| Lee, J | 4 |
| Rha, JH | 2 |
| Ahn, SH | 2 |
| Seo, WK | 3 |
| Park, JM | 2 |
| Lee, JH | 2 |
| Kwon, JH | 2 |
| Sohn, SI | 2 |
| Jung, JM | 2 |
| Navarro, JC | 2 |
| Kim, HY | 1 |
| Kim, EG | 1 |
| Kim, S | 1 |
| Cha, JK | 1 |
| Park, MS | 1 |
| Nam, HS | 1 |
| Kang, DW | 2 |
| Aoki, J | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Fujimoto, S | 1 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 1 |
| Nomura, K | 1 |
| Abe, K | 1 |
| Uno, M | 1 |
| Okada, Y | 2 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 1 |
| Yonehara, T | 1 |
| Inoue, T | 1 |
| Yagita, Y | 1 |
| Kimura, K | 2 |
| Hoshino, H | 1 |
| Toyoda, K | 1 |
| Omae, K | 1 |
| Ishida, N | 1 |
| Uchiyama, S | 1 |
| Sakai, N | 1 |
| Tanaka, K | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Isobe, M | 1 |
| Minematsu, K | 1 |
| Matsumoto, M | 1 |
| Tominaga, T | 1 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 1 |
| Yamaguchi, T | 1 |
| Sumbria, RK | 1 |
| Vasilevko, V | 1 |
| Grigoryan, MM | 1 |
| Paganini-Hill, A | 1 |
| Kim, R | 1 |
| Cribbs, DH | 1 |
| Fisher, MJ | 1 |
| Lee, EJ | 1 |
| Choi, PK | 1 |
| Chung, JY | 1 |
| Lee, SJ | 1 |
| Kang, HG | 1 |
| Kitashoji, A | 1 |
| Egashira, Y | 1 |
| Mishiro, K | 2 |
| Suzuki, Y | 1 |
| Ito, H | 2 |
| Tsuruma, K | 3 |
| Shimazawa, M | 3 |
| Hara, H | 4 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Shi, L | 1 |
| Pu, J | 1 |
| Xu, L | 1 |
| Malaguit, J | 1 |
| Zhang, J | 1 |
| Chen, S | 1 |
| Lee, JY | 1 |
| Takagi, T | 1 |
| Imai, T | 1 |
| Ishisaka, M | 1 |
| Tsujimoto, M | 1 |
| Nagashima, K | 1 |
| Matsukawa, H | 1 |
| Yoshimura, S | 2 |
| Kozawa, O | 1 |
| Iwama, T | 2 |
| Yu, KH | 1 |
| Oh, MS | 1 |
| Nonaka, Y | 1 |
| Goto, S | 1 |
| Toda, E | 1 |
| Ishiguro, M | 1 |
| Kim, JS | 1 |
| Shinohara, Y | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Liu, W | 1 |
| Liu, R | 1 |
| Sun, W | 1 |
| Peng, Q | 1 |
| Zhang, W | 2 |
| Xu, E | 2 |
| Cheng, Y | 2 |
| Ding, M | 2 |
| Li, Y | 2 |
| Hong, Z | 2 |
| Wu, J | 2 |
| Zeng, J | 2 |
| Yao, C | 2 |
| Huang, Y | 2 |
| Li, Z | 1 |
| Gao, X | 1 |
| Fan, D | 1 |
| Wong, K | 1 |
| Lu, C | 1 |
| Xiao, J | 1 |
| Hankey, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for cilostazol and Cerebral Hemorrhage
| Article | Year |
|---|---|
The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis.
Topics: Acute Disease; Asian People; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Chronic Disease; Cil | 2014 |
[Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].
Topics: Animals; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cyclic AMP; Disease Models, Animal; Endoth | 2011 |
9 trials available for cilostazol and Cerebral Hemorrhage
| Article | Year |
|---|---|
Prior intracerebral hemorrhage and white matter hyperintensity burden on recurrent stroke risk.
Topics: Aged; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2021 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cilostazol; Clopidogrel; Drug Therapy, Combination; Dual Anti-Pl | 2021 |
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study.
Topics: Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Common; Carotid Inti | 2017 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; | 2015 |
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
Topics: Adult; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cognition Disorder | 2016 |
Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.
Topics: Aspirin; Blood Pressure; Brain; Brain Diseases; Cerebral Hemorrhage; Cilostazol; Disease Progression | 2012 |
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female; | 2008 |
12 other studies available for cilostazol and Cerebral Hemorrhage
| Article | Year |
|---|---|
Functional Investigation of Meningeal Lymphatic System in Experimental Intracerebral Hemorrhage.
Topics: Animals; Brain; Cerebral Hemorrhage; Cilostazol; Lymphangiogenesis; Lymphatic System; Male; Meninges | 2022 |
Microbleeds and clinical outcome in acute mild stroke patients treated with antiplatelet therapy: ADS post-hoc analysis.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cilostazol; Dual Anti-Platelet Therapy; Female; Humans; Magnetic | 2021 |
Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages.
Topics: Animals; Cerebral Hemorrhage; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Deletio | 2017 |
Recurrent cerebral microbleeds with acute stroke symptoms: A case report.
Topics: Aged; Basal Ganglia Cerebrovascular Disease; Brain; Cerebral Hemorrhage; Cilostazol; Cognitive Dysfu | 2018 |
Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice.
Topics: Animals; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Endothelium, Vascular; Mal | 2013 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Cell Death; Cerebral Hemorrhage; Cilostazol; Collagenases; Endothelial | 2017 |
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.
Topics: Animals; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Disease Models | 2009 |
Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention.
Topics: Asia; Cerebral Hemorrhage; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Coronary Disease; Eur | 2009 |
Cilostazol: a drug particularly effective for Asians?
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders | 2011 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Data Interpretation, Statistical; Dose-Res | 2008 |